Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dai Kitagawa

Showing results (1-10 of 66) with videos related to

Pageof 7
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 15, 2007
[The differences of standard therapy for breast cancer between Europe/America and Japan--chemotherapy, operation,and radiotherapy]Dai Kitagawa, Shigehira Saji
Nihon Rinsho. Japanese Journal of Clinical Medicine|January 29, 2013
[The significance for prognostic factor of pathological complete response (pCR) after neoadjuvant chemotherapy]Dai Kitagawa, Katsumasa Kuroi
Nihon Rinsho. Japanese Journal of Clinical Medicine|August 8, 2007
[Current status and the perspective of treatment strategy for the patients with advanced or recurrent breast cancer]Dai Kitagawa, Masakazu Toi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2024
Are Oral Selective Estrogen Receptor Degraders Beneficial for Patients With <i>ESR1</i>-Mutated Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer?Aoba Okeya, Akihiko Shimomura, Dai Kitagawa, et al.
The Lancet. Oncology|January 5, 2023
Effective treatment based on monitoring bESR1 mutationsHoshie Hirai, Akihiko Shimomura, Dai Kitagawa, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 6, 2019
[Study of the Treatment for Colorectal Cancer(CRC)in Elderly People Aged 80 Years or Older]Hirofumi Hasegawa, Dai Kitagawa, Koutaro Shibahara, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|February 4, 2018
[A Case Involving the Re-Application of TAE for the Rupture of Recurrent Dissemination Lesion after Initial TAE and Hepatectomy Was Performed for A Previous Rupture of HCC]Shigeru Ueda, Hirofumi Hasegawa, Dai Kitagawa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2021
Regarding the Appropriate Target and Duration of Chemoprevention in Breast CancerTakahito Suemasu, Akihiko Shimomura, Chikako Shimizu, et al.
Journal of Nippon Medical School = Nippon Ika Daigaku Zasshi|July 8, 2014
Comparison of outcomes between women with de novo stage IV and relapsed breast cancerDai Kitagawa, Shin-ichiro Horiguchi, Toshinari Yamashita, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 14, 2018
[Giant Retroperitoneal Liposarcoma Treated by Surgical Resection and Chemotherapy - A Case Report]Hirofumi Hasegawa, Shoichi Inokuchi, Dai Kitagawa, et al.
Pageof 7

Showing results (1-10 of 66) with videos related to

Sort By:
Pageof 7
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 15, 2007
[The differences of standard therapy for breast cancer between Europe/America and Japan--chemotherapy, operation,and radiotherapy]Dai Kitagawa, Shigehira Saji
Nihon Rinsho. Japanese Journal of Clinical Medicine|January 29, 2013
[The significance for prognostic factor of pathological complete response (pCR) after neoadjuvant chemotherapy]Dai Kitagawa, Katsumasa Kuroi
Nihon Rinsho. Japanese Journal of Clinical Medicine|August 8, 2007
[Current status and the perspective of treatment strategy for the patients with advanced or recurrent breast cancer]Dai Kitagawa, Masakazu Toi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2024
Are Oral Selective Estrogen Receptor Degraders Beneficial for Patients With <i>ESR1</i>-Mutated Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer?Aoba Okeya, Akihiko Shimomura, Dai Kitagawa, et al.
The Lancet. Oncology|January 5, 2023
Effective treatment based on monitoring bESR1 mutationsHoshie Hirai, Akihiko Shimomura, Dai Kitagawa, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 6, 2019
[Study of the Treatment for Colorectal Cancer(CRC)in Elderly People Aged 80 Years or Older]Hirofumi Hasegawa, Dai Kitagawa, Koutaro Shibahara, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|February 4, 2018
[A Case Involving the Re-Application of TAE for the Rupture of Recurrent Dissemination Lesion after Initial TAE and Hepatectomy Was Performed for A Previous Rupture of HCC]Shigeru Ueda, Hirofumi Hasegawa, Dai Kitagawa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2021
Regarding the Appropriate Target and Duration of Chemoprevention in Breast CancerTakahito Suemasu, Akihiko Shimomura, Chikako Shimizu, et al.
Journal of Nippon Medical School = Nippon Ika Daigaku Zasshi|July 8, 2014
Comparison of outcomes between women with de novo stage IV and relapsed breast cancerDai Kitagawa, Shin-ichiro Horiguchi, Toshinari Yamashita, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 14, 2018
[Giant Retroperitoneal Liposarcoma Treated by Surgical Resection and Chemotherapy - A Case Report]Hirofumi Hasegawa, Shoichi Inokuchi, Dai Kitagawa, et al.
Pageof 7